EVE Health Group (ASX: EVE) has appointed its first dedicated medical science liaison (MSL) to lead national medical education and prescriber engagement programs across Australia.
The appointment represents a significant expansion of the company’s medical capability following the launch of its Dyspro women’s formulation, and ahead of the commercial rollout of men’s health product Libbo.
EVE said the new role strengthens its commitment to supporting prescribers with clinical data, education, and ongoing medical engagement as part of its commercial growth strategy.
Expanding Clinical Capability
The MSL will focus on communication and collaboration with general practitioners, specialists, and nurse practitioners to build awareness of EVE’s cannabinoid-based and oral dissolving film therapies.
The position will provide direct scientific support, organise training sessions, and ensure prescribers remain informed about the latest product data and patient outcomes.
EVE sees the role as integral to building clinical confidence and expanding access to Dyspro and Libbo, which target unmet needs in dysmenorrhoea, endometriosis, and erectile dysfunction.
Plans are already underway to expand the MSL team in 2026 in response to growing demand from healthcare professionals.
The company will continue to evolve its broader medical engagement framework alongside the commercial rollout of Dyspro and Libbo, ensuring clinical education scales with market adoption.
Supporting Prescriber Education
“Building a dedicated MSL capability is an important milestone in EVE’s evolution as a pharmaceutical company,” chief executive officer Damian Wood said.
“Our goal is to make sure prescribers have the confidence and resources to use our products effectively—this appointment ensures we continue to back that growth with clinical education and medical engagement.”
The new MSL will work closely with internal teams to coordinate educational initiatives, develop prescriber resources, and support the ongoing collection of real-world data.
These activities will underpin EVE’s strategy to strengthen its position in both women’s and men’s health markets while ensuring product information is delivered accurately and responsibly to the medical community.
